Lötjönen Johannes, Kurra Venla, Laivuori Hannele, Bjelogrlić Nina
Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Department of Clinical Genetics, Tampere University Hospital, Tampere, Finland.
Mol Genet Genomic Med. 2025 Feb;13(2):e70056. doi: 10.1002/mgg3.70056.
MECP2 variants cause X-chromosome-linked rare developmental syndromes. Typically, the mutation is sporadic, occurs in females and is fatal in men. Accurate genetic and clinical diagnostics are considered essential for the management of symptoms and the development of new treatments. These aims may be difficult to reach before more is known about factors resulting in highly variable clinical pictures among patients carrying the same MECP2 variant. We describe the clinical picture of two brothers carrying the same MECP2 variant and compare them with cases published in the literature.
Most of the MECP2 mutations are known to be de novo mutations, which is why the recurrence of the mutation in the couple's other children is unlikely. Unexpectedly, our routine genetic testing revealed a 23-year-old man (P1) and his younger brother (P2) to carry the same hemizygous pathogenic missense variant c.419C>T, p.(Ala140Val) (transcript NM_004992.3) of MECP2, which was found to be inherited from their presumably asymptomatic mother. Thus, further clinical evaluation and comparison with literature cases was considered necessary.
The P1 has a severe syndromic intellectual disorder (ID), whereas his brother has a substantially milder ID predominantly limited to problems in verbal skills. Neither P1 nor his younger brother has been diagnosed with Rett syndrome. The P1 (unlike his younger brother) has several lingual, social and motor difficulties; disruptive behavior was the most difficult symptom to treat. P1's response to several medical and non-medical treatment trials has remained inadequate, thus requiring the patient to be hospitalised for a long time. The literature review revealed that apart from our family, there are five other families with more than one male carrying the same MECP2 p.Ala140Val mutation, such as P1 and P2. The phenotypes of all 24 men from us (n = 2) and others (n = 22) carrying the same, presumably non-lethal mutation show great variability.
The p.Ala140Val mutation of MECP2 in males is associated with a rare X-chromosomal developmental disorder with highly variable phenotypes. Further studies are needed to better understand all those influencing factors that can explain phenotypic differences within the same genotype to find optimal medicinal therapies.
MECP2基因变异可导致X染色体连锁的罕见发育综合征。通常,该突变是散发性的,发生在女性中,对男性则是致命的。准确的基因和临床诊断被认为对于症状管理和新治疗方法的开发至关重要。在对携带相同MECP2基因变异的患者中导致临床症状高度可变的因素有更多了解之前,这些目标可能难以实现。我们描述了两名携带相同MECP2基因变异的兄弟的临床表现,并将他们与文献中报道的病例进行比较。
已知大多数MECP2突变是新发突变,这就是为什么该突变在这对夫妇的其他孩子中复发的可能性不大。出乎意料的是,我们的常规基因检测发现一名23岁男性(P1)及其弟弟(P2)携带相同的MECP2基因半合子致病性错义变异c.419C>T,p.(Ala140Val)(转录本NM_004992.3),该变异被发现是从他们可能无症状的母亲那里遗传而来。因此,有必要进行进一步的临床评估并与文献中的病例进行比较。
P1患有严重的综合征性智力障碍(ID),而他的弟弟ID症状则明显较轻,主要局限于语言技能方面的问题。P1和他的弟弟均未被诊断为雷特综合征。P1(与他的弟弟不同)存在一些语言、社交和运动方面的困难;破坏性行为是最难治疗的症状。P1对多种医学和非医学治疗试验的反应均不理想,因此需要患者长期住院。文献综述显示,除了我们这个家庭外,还有其他五个家庭有不止一名男性携带相同的MECP2 p.Ala140Val突变,如P1和P2。我们(n = 2)和其他(n = 22)携带相同的、可能非致命突变的所有24名男性的表型显示出很大的变异性。
男性中MECP2的p.Ala140Val突变与一种罕见的X染色体发育障碍相关,其表型高度可变。需要进一步研究以更好地理解所有那些能够解释同一基因型内表型差异的影响因素,从而找到最佳的药物治疗方法。